File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Potential Use of the Adenosine Triphosphate Cell Viability Assay in Endometrial Cancer

TitlePotential Use of the Adenosine Triphosphate Cell Viability Assay in Endometrial Cancer
Authors
KeywordsATP cell viability assay
chemosensitivity
endometrial cancer
Issue Date2006
PublisherSage Publications, Inc. The Journal's web site is located at http://rsx.sagepub.com
Citation
Journal Of The Society For Gynecologic Investigation, 2006, v. 13 n. 7, p. 518-522 How to Cite?
AbstractObjective: Adenosine triphosphate cell viability assay (ATP-CVA) was used previously to evaluate chemotherapy in uterine cancer cell lines. In this study, we have performed the ATP-CVA on endometrial cancer patients to study the feasibility of using ATP-CVA in endometrial cancer to determine the intrinsic chemosensitivity of the cytotoxic drugs. Methods: Thirty-three patients with endometrial adenocarcinoma who presented for a staging operation were recruited. Endometrial cancer samples were obtained at the time of operation. In vitro ATP-CVA and chemosensitivity testing was performed using cisplatin, carboplatin, paclitaxel, etoposide, doxorubicin, 4-epidoxorubicin, and topotecan. Results: Thirty-two of the 33 endometrial cancer samples were evaluable for SF50 (survival fraction at 50% of the peak plasma concentration [PPC]) using ATP-CVA. The median SF50 of carboplatin (0.33) was significantly less than the median SF50 of cisplatin (0.71), topotecan (0.93), paclitaxel (0.68), doxorubicin (1.0), etoposide (0.70), or 4-epidoxorubicin (0.88) (Wilcoxon signed rank test, P <.001). Conclusion: This study showed the feasibility of using the ATP-CVA in endometrial cancer to determine the intrinsic chemosensitivity of cytotoxic drugs. © 2006 Society for Gynecologic Investigation.
Persistent Identifierhttp://hdl.handle.net/10722/87354
ISSN
2008 Impact Factor: 2.333
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTam, KFen_HK
dc.contributor.authorNg, TYen_HK
dc.contributor.authorTsang, PCKen_HK
dc.contributor.authorLi, CFen_HK
dc.contributor.authorNgan, HYSen_HK
dc.date.accessioned2010-09-06T09:28:35Z-
dc.date.available2010-09-06T09:28:35Z-
dc.date.issued2006en_HK
dc.identifier.citationJournal Of The Society For Gynecologic Investigation, 2006, v. 13 n. 7, p. 518-522en_HK
dc.identifier.issn1071-5576en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87354-
dc.description.abstractObjective: Adenosine triphosphate cell viability assay (ATP-CVA) was used previously to evaluate chemotherapy in uterine cancer cell lines. In this study, we have performed the ATP-CVA on endometrial cancer patients to study the feasibility of using ATP-CVA in endometrial cancer to determine the intrinsic chemosensitivity of the cytotoxic drugs. Methods: Thirty-three patients with endometrial adenocarcinoma who presented for a staging operation were recruited. Endometrial cancer samples were obtained at the time of operation. In vitro ATP-CVA and chemosensitivity testing was performed using cisplatin, carboplatin, paclitaxel, etoposide, doxorubicin, 4-epidoxorubicin, and topotecan. Results: Thirty-two of the 33 endometrial cancer samples were evaluable for SF50 (survival fraction at 50% of the peak plasma concentration [PPC]) using ATP-CVA. The median SF50 of carboplatin (0.33) was significantly less than the median SF50 of cisplatin (0.71), topotecan (0.93), paclitaxel (0.68), doxorubicin (1.0), etoposide (0.70), or 4-epidoxorubicin (0.88) (Wilcoxon signed rank test, P <.001). Conclusion: This study showed the feasibility of using the ATP-CVA in endometrial cancer to determine the intrinsic chemosensitivity of cytotoxic drugs. © 2006 Society for Gynecologic Investigation.en_HK
dc.languageengen_HK
dc.publisherSage Publications, Inc. The Journal's web site is located at http://rsx.sagepub.comen_HK
dc.relation.ispartofJournal of the Society for Gynecologic Investigationen_HK
dc.rightsJournal of the Society for Gynecologic Investigation. Copyright © Sage Publications, Inc.en_HK
dc.subjectATP cell viability assayen_HK
dc.subjectchemosensitivityen_HK
dc.subjectendometrial canceren_HK
dc.titlePotential Use of the Adenosine Triphosphate Cell Viability Assay in Endometrial Canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1071-5576&volume=13&issue=7&spage=518&epage=522&date=2006&atitle=Potential+use+of+the+adenosine+triphosphate+cell+viability+assay+in+endometrial+canceren_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.jsgi.2006.06.004en_HK
dc.identifier.pmid16979354-
dc.identifier.scopuseid_2-s2.0-33749529277en_HK
dc.identifier.hkuros131633en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33749529277&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume13en_HK
dc.identifier.issue7en_HK
dc.identifier.spage518en_HK
dc.identifier.epage522en_HK
dc.identifier.isiWOS:000241565600009-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridTam, KF=35622901400en_HK
dc.identifier.scopusauthoridNg, TY=7402229853en_HK
dc.identifier.scopusauthoridTsang, PCK=7102404070en_HK
dc.identifier.scopusauthoridLi, CF=14830505800en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats